1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
C-Rad AB (publ)

C-Rad AB (publ)

CRAD-B.ST
C-Rad AB (publ)SE flagStockholm Stock Exchange
33.90
SEK
-0.20
- -
1.09BMarket Cap
C-Rad AB (publ)
CRAD-B.ST
(Stockholm Stock Exchange)

Recent

price

33.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.1
0.89
1.54
2.45
2.61
3.1
3.22
4.5
6.18
6.64
6.66
7.74
8.92
12.57
13.89
13.09
13.18
Revenue per Share
-0.76
-2.55
-1.16
-1.14
-0.35
-0.99
-1.21
-0.37
0.69
-0.45
0.43
0.74
0.22
1.05
1.67
0.31
0.76
Basic EPS, GAAP
-1.1
-1.59
-0.95
-1.52
-0.92
-1.37
-1.87
-0.17
-0.44
0.38
0.51
0.5
0.25
0.87
0.86
1.86
1.24
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-3.2
-4.99
-6.17
-6.69
-6.51
-7.21
-7.18
-6.61
-5.66
-6.07
-5.21
-4.39
-4.16
-3.11
-1.44
-1.13
- -
Book Value per Share
0.81
1.07
0.17
1.39
0.95
0.57
1.7
1.46
2.17
2.12
5.47
6.35
6.54
7.14
8.74
9.13
9.11
Tangible Book Value per Share
13
17
17
18
20
21
26
30
31
31
33
34
34
34
34
34
34
Basic Weighted Avg Shares
14
15
26
45
53
66
83
133
190
205
222
261
301
425
469
442
446
Sales/Revenue/Turnover
-66.18
-159.77
-73.39
-45.11
-33.44
-34.49
-36.95
-6.93
1.6
-3.79
9.06
14
7.22
11.73
15.02
13.72
12.66
Operating Margin (%)
3
26
5
6
6
6
6
5
7
21
9
10
10
9
10
10
11
Depreciation Expense
-10
-43
-19
-21
-7
-21
-31
-11
21
-14
14
25
7
36
56
10
26
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
12.31
29.76
65.19
19.12
29.25
34.04
42.63
Effective Tax Rate (%)
-69.11
-285.76
-75.22
-46.62
-13.43
-32.02
-37.76
-8.19
11.15
-6.72
6.48
9.61
2.48
8.37
12.04
2.37
5.77
Profit Margin (%)
18
27
9
21
20
13
46
34
37
55
153
195
215
232
288
296
298
Working Capital
6
10
9
12
17
12
12
- -
- -
20
7
6
4
2
9
9
10
LT Debt
48
36
16
38
38
40
71
71
94
83
200
231
243
271
325
347
341
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
11.32
11.56
3.13
15.53
15.83
10.98
9.87
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-9.01
-16.41
-5.48
-29.89
-79.29
-32.4
446.96
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
9
11
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
34
34
34
Market Capitalization
1,014
957
1,215

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
441
414
421
Cash, Cash Equivalents & STI
151
161
158
Accounts Receivable, Net
164
140
158
Inventories
53
51
49
Total Current Liabilities
153
123
124
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
29.64%
11.83%
6.85%
Free Cash Flow
31.56%
61.26%
114.63%
Net Income, GAAP
-32.42%
71.4%
-81.47%
Sales/Revenue/Turnover
22.35%
15.76%
-5.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
118
129
100
122
469
2025
119
105
106
- -
442
2026
105
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.48
0.31
0.45
0.43
1.67
2025
-0.24
0.12
0.05
- -
0.31
2026
0.33
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
EBR Systems, Inc. (EBR.AX)
CardieX Limited (CDX.AX)
PCL, Inc. (241820.KQ)
Senzime AB (publ) (SNZZF)
Medinice S.A. (ICE.WA)
Aethlon Medical, Inc. (AEMD)
Business
C-Rad AB (publ) develops, manufactures and markets surface guided radiation therapy (SGRT) systems and related solutions to enhance precision, safety and efficiency in cancer radiotherapy treatments worldwide. The company's core products include the Catalyst+ HD platform for high-precision patient positioning, intra-fraction motion management and respiratory gating in stereotactic and conventional treatments; Catalyst+ for patient setup, breath-hold reproducibility and online tracking; Catalyst+ PT tailored for particle and proton therapy; Catalyst+ HD Ring Gantry for non-coplanar deliveries; Sentinel 4DCT laser-based optical surface scanning system for positioning and monitoring; cAutoVerify automation software for imaging and accessory validation; cAccessory for treatment accessory registration; and supporting tools such as SmartPhantom RT motorized laser alignment devices, StaticPhantom for laser verification, and high-impact technology (HIT) patient positioning lasers including HIT5, HIT3 and HIT1 models; alongside comprehensive services encompassing installation, maintenance, software upgrades and training. Founded in 2004 and headquartered in Uppsala, Sweden, C-Rad AB operates as the parent of the C-Rad group through subsidiaries including C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, with sales offices and support in the United States, Germany, France, China, Australia, New Zealand and distributors across Europe, Asia-Pacific, Latin America and other regions serving radiation oncology clinics and hospitals. Recent developments encompass new product enhancements unveiled at ESTRO 2025 including an entry-level SGRT solution upgradable to Catalyst+ HD and ergonomic workflow improvements; a strategic partnership with iRT Systems GmbH to advance radiotherapy safety through integrated surface-guided positioning and real-time beam monitoring; leadership changes with Linda Frölén appointed as permanent CFO in June 2024 succeeding interim CFO Jonas Reinhammar; a major 10 MSEK order win for Latin American expansion in Mexico in October 2024; medium-term financial targets announced in May 2025 alongside a solid Q1 2025 interim report reflecting order intake recovery and growth in EMEA and Americas; ongoing collaborations with vendors such as RaySearch Laboratories, Mevion Medical Systems and historical partners Elekta and Varian; and showcase of industry-leading partnerships plus advanced SGRT at ASTRO 2024.